Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen (NASDAQ:BIIB) stock traded flat as the company reports better than expected Q4 2024 financials, but its 2025 outlook ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales ...

(Reuters) - Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis. Investors sold Biogen ...

Citi lowered the firm’s price target on Biogen (BIIB) to $145 from $160 and keeps a Neutral rating on the shares post the Q4 report. The ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

Total revenue is expected to decline by a mid-single digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis ...

(Reuters) -Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.